William Collins is a partner in Goodwin’s nationally recognized Life Sciences group, counseling clients in the industries of biotechnology, pharmaceuticals and medical devices. Serving as his clients’ principal outside counsel, Mr. Collins provides strategic advice and corporate legal counseling to management teams and boards while structuring and leading significant transactions on his clients’ behalf. He is recognized by his clients and colleagues for his extensive industry knowledge and deal experience, and for providing practical legal and business advice. Mr. Collins has also been recognized as one of Law360’s Rising Stars for 2022.

Mr. Collins has extensive experience with startup and formation matters, venture capital financings, initial public offerings, deSPAC transactions and other equity debt capital markets transactions, mergers and acquisitions, strategic collaborations, and other complex transactions. He also represents a number of publicly traded biotechnology companies in ongoing SEC compliance, capital raising and corporate governance matters.

Mr. Collins has advised many of his clients through their full corporate life cycle, starting with their initial founding and funding. He also regularly represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments, exits and secondary stock sale transactions. 

Experience

工作经历

EXPÉRIENCE

ERFAHRUNG

Mr. Collins’s recent client representations include the following:

Representative Matters

代表事项

REFERENZMANDATE

General Corporate Counseling and Significant Transactions
  • Kymera Therapeutics in connection with its $30 million Series A financing, $65 million Series B financing and its $102 million Series C financing, its strategic collaborations with Vertex Pharmaceuticals and Sanofi, its $200 million initial public offering, its $200 million follow-on public offering, and $150 million PIPE.
  • Relay Therapeutics in connection with its $57 million Series A financing, its $63 million Series B financing and its $400 million Series C financing, its $460 million initial public offering, and multiple follow-on offerings of more than $300 million, and its $85 million acquisition of ZebiAI.
  • EQRx in connection with its $200 million Series A financing and $500 million Series B Financing, its $5.35 billion business combination with CM Life Sciences III, including its $1.2 billion PIPE financing.
  • Nimbus Therapeutics in connection with its multi-target strategic alliance with Celgene Corporation in immunology, the $1.2 billion sale of its ACC inhibitor program to Gilead Biosciences, its $60 million financing, $105 million financing and $125 million financing completed since 2020.
  • Forma Therapeutics in connection with its $100 million Series D financing, its $319.3 million initial public offering, its $275.8 million follow-on public offering, its $200 million “at-the-market” offering, and its $1.1 billion sale to Novo Nordisk.
  • ROME Therapeutics with its $50 million Series A financing and $77 million Series B financing
  • Accent Therapeutics in its $63.5 million Series B financing
  • Tango Therapeutics in connection with its $55 million Series A financing and its $60 million Series B financing, and its $1.0 billion definitive business combination with BCTG Acquisition Corp.
  • Magenta Therapeutics in connection with its $48.5 million Series A financing and its $50 million Series B financing, and its $100 million initial public offering
  • Intellia Therapeutics in connection with its foundational license agreement with Caribou Biosciences pursuant to which Intellia has the right to therapeutic applications of CRISPR/Cas9 technology, its collaboration and license agreements with Novartis and Regeneron, its $124.2 million initial public offering, and its $150 million follow-on public offering
  • Obsidian Therapeutics in connection with its $49.5 million Series A financing and $115 million Series B financing, and its strategic collaboration with Celgene Corporation
  • Disc Medicine in connection with its $50 million Series A financing and its $90 million Series B financing, and its reverse merger transaction with Gemini Therapeutics
  • Ikena Oncology in connection with its $120 million Series B financing and its $143.8 million initial public offering
  • Orionis Biosciences in its research collaboration and financing transaction with Novartis
  • Sionna Therapeutics in its $111 million Series B financing
  • HotSpot Therapeutics, Inc. in its $100 million Series C financing
  • Oak Hill Bio in its formation, financing and acquisition of three programs from Takeda
Issuer-Side Capital Markets Transactions
  • Rocket Pharmaceuticals in its $299 million follow-on financing
  • Candel Therapeutics in its $72 million initial public offering
  • Praxis Precision Medicines in its $104.9 million underwritten public offering
  • TCR2 Therapeutics in its $75 million underwritten public offering
  • Bluebird bio in its $116.1 million initial public offering
  • Other clinical stage and commercial stage issuers in more than $5 billion in equity and debt offerings
Mergers and Acquisitions
  • Thrive Earlier Detection Corp. in connection with its $2.15 billion sale to Exact Sciences Corporation
  • Rodin Therapeutics in its $950 million sale to Alkermes
  • Padlock Therapeutics in its $600 million sale to Bristol-Meyers Squibb
  • Ocata Therapeutics in its sale to Astellas
  • Albany Molecular Research Inc. in its sale to The Carlyle Group and GTCR
  • Outcome Sciences in its sale to Quintiles Transnational (NASDAQ: Q)
  • ZOLL Medical in its acquisition of Kyma Medical Systems and other business development transactions

Mr. Collins also represents leading life science venture capital and investment firms, including Atlas Venture, Third Rock Ventures, Curie Bio, Newpath Partners, Bain Capital Life Sciences, Lightstone Ventures, Vida Ventures and others, in connection with their portfolio investments and related matters.

Professional Activities

Mr. Collins is a member of the Boston and American Bar Associations.

Professional Experience

Prior to joining Goodwin, Mr. Collins was an Economic Justice Fellow at the Lawyers’ Committee for Civil Rights, where he coordinated with community groups and local attorneys to bring pro bono business legal services to low-income and minority entrepreneurs in Eastern Massachusetts. Mr. Collins continues to be an active participant in Goodwin’s Neighborhood Business Initiative, which has for more than 15 years served the legal needs of low-income and minority entrepreneurs in the Greater Boston area.

Recognition

Mr. Collins is consistently recognized by Legal 500 for his work as a leader in Life Sciences Venture Capital work. While attending law school, Mr. Collins was Editor-in-Chief of the Review of Banking and Financial Law.

In The News

相关新闻

ACTUALITÉS

MELDUNGEN

Credentials

专业资格

RÉFÉRENCES

WERDEGANG

Education

JD, 2009
Boston University School of Law

(cum laude)

BS, 2006
The University of Texas at Dallas

(cum laude)

Admissions

Bar

Massachusetts
Profile Image
Get In Touch
联系我们
NOUS CONTACTER
Kontakt
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
搜寻其他律师
Recherche par Pratique
ANWALTSSUCHE